Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date

被引：71

作者：

Cinti, Francesca ^{[1
]}

Moffa, Simona ^{[1
]}

Impronta, Flavia ^{[1
]}

Cefalo, Chiara M. A. ^{[1
]}

Sun, Vinsin A. ^{[1
]}

Sorice, Gian Pio ^{[1
]}

Mezza, Teresa ^{[1
]}

Giaccari, Andrea ^{[1
]}

机构：

[1] Univ Cattolica Sacro Cuore, Ctr Endocrine & Metab Dis, Fdn Policlin Univ A Gemelli, Largo A Gemelli 8, I-00168 Rome, Italy

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2017年 / 11卷

关键词：

antidiabetic drugs; glycosylated hemoglobin; glycemic control; sodium-glucose cotransporter 2 inhibitors; precision medicine; type 1 diabetes mellitus; type 2 diabetes mellitus; weight reduction; GLUCOSE COTRANSPORTER 2; SGLT2; INHIBITORS; CLINICAL CANDIDATE; GLYCEMIC CONTROL; BLOOD-PRESSURE; OUTCOME TRIAL; EFFICACY; SAFETY; DAPAGLIFLOZIN; EMPAGLIFLOZIN;

D O I：

10.2147/DDDT.S114932

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the latest therapeutic strategy in the treatment of type 2 diabetes mellitus (T2DM). Using an insulin-independent mechanism (glycosuria), they reduce glucose toxicity and improve insulin sensitivity and beta-cell function. The promising results obtained in clinical trials show that SGLT2 significantly improves glycemic control and provides greater cardiovascular protection, combined with a reduction in body weight and blood pressure (BP). This review focuses on ertugliflozin, a new, highly selective, and reversible SGLT2 inhibitor. Clinical trials published to date show that ertugliflozin, both as a monotherapy and as an add-on to oral antidiabetic agents, is safe and effective in reducing glycosylated hemoglobin (HbA1c), body weight, and BP in T2DM patients.

引用

页码：2905 / 2919

页数：15

共 68 条

[1] Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial [J].

Abdul-Ghani, M. A. ;

Puckett, C. ;

Triplitt, C. ;

Maggs, D. ;

Adams, J. ;

Cersosimo, E. ;

DeFronzo, R. A. .

DIABETES OBESITY & METABOLISM, 2015, 17 (03) :268-275

[2] Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin [J].

Amin, N. B. ;

Wang, X. ;

Jain, S. M. ;

Lee, D. S. ;

Nucci, G. ;

Rusnak, J. M. .

DIABETES OBESITY & METABOLISM, 2015, 17 (06) :591-598

[3]

Aronson R, 2017, ADA 2017 JUN 8 SAN D

[4] Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis [J].

Baker, William L. ;

Smyth, Lindsay R. ;

Riche, Daniel M. ;

Bourret, Emily M. ;

Chamberlin, Kevin W. ;

White, William B. .

JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2014, 8 (04) :262-275

[5] Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin [J].

Bolinder, J. ;

Ljunggren, O. ;

Johansson, L. ;

Wilding, J. ;

Langkilde, A. M. ;

Sjostrom, C. D. ;

Sugg, J. ;

Parikh, S. .

DIABETES OBESITY & METABOLISM, 2014, 16 (02) :159-169

[6]

Castaneda Francisco, 2007, Int J Med Sci, V4, P131

[7] Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial [J].

Cefalu, William T. ;

Leiter, Lawrence A. ;

Yoon, Kun-Ho ;

Arias, Pablo ;

Niskanen, Leo ;

Xie, John ;

Balis, Dainius A. ;

Canovatchel, William ;

Meininger, Gary .

LANCET, 2013, 382 (9896) :941-950

[8] SGLT2 inhibition - a novel strategy for diabetes treatment [J].

Chao, Edward C. ;

Henry, Robert R. .

NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (07) :551-559

[9] Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes [J].

Cherney, David Z. I. ;

Perkins, Bruce A. ;

Soleymanlou, Nima ;

Xiao, Fengxia ;

Zimpelmann, Joseph ;

Woerle, Hans-Juergen ;

Johansen, Odd E. ;

Broedl, Uli C. ;

von Eynatten, Maximilian ;

Burns, Kevin D. .

KIDNEY INTERNATIONAL, 2014, 86 (05) :1057-1058

[10]

Dash RP, 2016, XENOBIOTICA, P1

← 1 2 3 4 5 6 7 →